Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.

MLA

Cohen, Stanley, et al. “Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-Cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.” Clinical Therapeutics, vol. 38, no. 6, June 2016, p. 1417–1434.e2. EBSCOhost, https://doi.org/10.1016/j.clinthera.2016.03.028.

APA

Cohen, S., Clowse, M., Pardo, P., Bhattacharya, I., Menon, S., Gourley, I., & Diehl, A. (2016). Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus. Clinical Therapeutics, 38(6), 1417–1434.e2. https://doi.org/10.1016/j.clinthera.2016.03.028

Chicago

Cohen, Stanley, Megan Clowse, Patricia Pardo, Indranil Bhattacharya, Sandeep Menon, Ian Gourley, and Annette Diehl. 2016. “Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-Cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus.” Clinical Therapeutics 38 (6): 1417–1434.e2. doi:10.1016/j.clinthera.2016.03.028.